Rheumatology
From the Journals
Too few RA patients get timely adjustment of DMARDs
The study is the first to examine time to DMARD therapy adjustment and time to low disease activity for RA patients with moderate to high disease...
Latest News
Launch of adalimumab biosimilar Amjevita postponed
Amgen reached a deal with AbbVie to settle its patent infringement litigation.
Conference Coverage
ACP osteoporosis treatment guideline debated
DENVER – An endocrinologist and a primary care physician debate the merits of the American College of Physicians osteoporosis treatment guideline...
Conference Coverage
Immunogenicity concerns for biosimilars so far don’t go beyond originator biologics
But there are few data available on the impact of antidrug antibodies to biosimilars across rheumatic diseases and on switching.
Conference Coverage
Early ankylosing spondylitis treatment stops transition from inflammatory to bone-forming fatty lesions
“The earlier we treat intensively, the better impact you have on structural outcomes,” according to Dirk Elewaut, MD, PhD.
Feature
ECHO rheumatology programs increase access, improve care
The University of Arizona is using the telemedicine-based ECHO model to train and provide support to primary care providers to treat rheumatic...
Conference Coverage
Romosozumab reduces fracture risk out to 36 months, with no signs of cardiovascular problems
Taking romosozumab followed by denosumab led to fewer fractures and greater bone density increases than did placebo followed by denosumab.
Conference Coverage
‘Multimorbidities’ in RA make impact on treatment efficacy, disease activity
The effects of two or more chronic conditions in patients with RA, such as obesity, fibromyalgia, depression, and anxiety, need to be considered...
Conference Coverage
Teriparatide reduces fractures over risedronate in all subgroups with osteoporosis
DENVER – “I don’t think it’s a question of if, but when to use an anabolic therapy,” Dr. Fahrleitner-Pammer said.
Conference Coverage
Preferred osteoporosis treatment order with teriparatide, denosumab reaffirmed
DENVER – The findings reinforce the use of an anabolic agent followed by an antiresorptive agent, rather than the other way around.
From the Journals
Survival in lupus patients has plateaued
Wealthier countries have generally fared better than low- and middle-income countries.